Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Assets Average (2016 - 2025)

Historic Assets Average for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $18.3 million.

  • Marker Therapeutics' Assets Average rose 6162.11% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 6162.11%. This contributed to the annual value of $19.6 million for FY2024, which is 2405.32% down from last year.
  • Per Marker Therapeutics' latest filing, its Assets Average stood at $18.3 million for Q3 2025, which was up 6162.11% from $15.9 million recorded in Q2 2025.
  • Marker Therapeutics' Assets Average's 5-year high stood at $84.4 million during Q2 2021, with a 5-year trough of $11.3 million in Q3 2024.
  • In the last 5 years, Marker Therapeutics' Assets Average had a median value of $24.9 million in 2023 and averaged $37.0 million.
  • Per our database at Business Quant, Marker Therapeutics' Assets Average soared by 8470.02% in 2021 and then plummeted by 5564.56% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Assets Average stood at $70.0 million in 2021, then tumbled by 46.07% to $37.8 million in 2022, then plummeted by 51.53% to $18.3 million in 2023, then decreased by 10.05% to $16.5 million in 2024, then increased by 10.84% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $15.9 million for Q2 2025, and $19.5 million during Q1 2025.